Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 9/20 | 0.50 |
| ▸ | PPARG | P37231 | 8/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12537289 | 0.91 | LDHA (0.47) | LDHAPPARDPPARGFFAR1CA12 | |
| SCHEMBL19221367 | 0.87 | FFAR1 (0.46) | LDHAPPARDPPARGFFAR1CA12 | |
| SCHEMBL524638 | 0.86 | ITGB3 (0.59) | FFAR1CA12CA1CA2CA7 | |
| SCHEMBL9784912 | 0.86 | ITGB3 (0.59) | FFAR1CA12CA1CA2CA7 | |
| SCHEMBL8970225 | 0.86 | FFAR1 (0.49) | LDHAPPARDPPARGFFAR1CA12 | |
| SCHEMBL455152 | 0.86 | ITGB3 (0.59) | FFAR1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL6775024 | 0.84 | ITGB3 (0.58) | FFAR1CA12CA1CA2CA7 | |
| SCHEMBL12907521 | 0.82 | FFAR1 (0.43) | LDHAPPARDPPARGFFAR1CA12 | |
| SCHEMBL3686436 | 0.80 | FFAR1 (0.59) | PPARDFFAR1MEN1KMT2A | |
| SCHEMBL19512313 | 0.80 | SLC1A1 (0.58) | FFAR1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7838548-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1697389-A4 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MAN CO LTD (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
| EP-1697389-A2 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050113345-A1 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| WO-2005039504-A2 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI CO., LTD. (JP) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | TLR2, TLR6, TLR3 | LDHA 1698/4885PPARD 416/4885PPARG 95/4885 |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | LDHA 1698/4885PPARD 416/4885PPARG 95/4885 |
| US-20050113345-A1 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | TLR2, TLR6, TLR3 | LDHA 1698/4885PPARD 416/4885PPARG 95/4885 |
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | LDHA 1698/4885PPARD 416/4885PPARG 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.